Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

<br /> Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium<br />

PR Newswire

DUBLIN

,

Jan. 18, 2022

/PRNewswire/ —

Alkermes plc

(Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place

Jan. 20-22, 2022

. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA
^®
), and preclinical data from the study of nemvaleukin in combination with novel agents in GI cancers.

Details of the presentation are as follows:

Abstract:

659

Title:

Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trial

Presenter:

Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology,

University of Michigan

Presentation Date:

The poster, along with a pre-recorded presentation, will be available on the ASCO GI virtual meeting platform beginning

Jan. 20, 2022

.

About Nemvaleukin Alfa (“nemvaleukin”)

Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the Nemvaleukin Clinical Development Program

ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA
^®
(pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include:

ARTISTRY-1

,

ARTISTRY-2

,

ARTISTRY-3

,

ARTISTRY-6

and

ARTISTRY-7

.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in

Dublin, Ireland

, Alkermes plc has an R&D center in

Waltham, Massachusetts

; a research and manufacturing facility in Athlone,

Ireland

; and a manufacturing facility in

Wilmington, Ohio

. For more information, please visit Alkermes’ website at

www.alkermes.com

.